DNLI
Price
$20.01
Change
-$0.52 (-2.53%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.35B
40 days until earnings call
Intraday BUY SELL Signals
NERV
Price
$3.28
Change
+$0.05 (+1.55%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
162.34M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs NERV

DNLI vs NERV Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DNLI vs. NERV commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and NERV is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DNLI vs NERV: Fundamental Ratings
DNLI
NERV
OUTLOOK RATING
1..100
5790
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5865
P/E GROWTH RATING
1..100
9998
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for DNLI (90). This means that NERV’s stock grew somewhat faster than DNLI’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that NERV’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (98) in the Biotechnology industry is in the same range as NERV (100). This means that DNLI’s stock grew similarly to NERV’s over the last 12 months.

DNLI's Price Growth Rating (58) in the Biotechnology industry is in the same range as NERV (65). This means that DNLI’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (98) in the Biotechnology industry is in the same range as DNLI (99). This means that NERV’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINERV
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (DNLI: $20.53 vs. NERV: $3.23)
Brand notoriety: DNLI and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 110% vs. NERV: 59%
Market capitalization -- DNLI: $3.35B vs. NERV: $162.34M
DNLI [@Biotechnology] is valued at $3.35B. NERV’s [@Biotechnology] market capitalization is $162.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green while NERV’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while NERV’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • NERV’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than NERV.

Price Growth

DNLI (@Biotechnology) experienced а +0.29% price change this week, while NERV (@Biotechnology) price change was -6.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

DNLI is expected to report earnings on Nov 11, 2026.

NERV is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DNLI
Daily Signal:
Gain/Loss:
NERV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CRWG18.790.58
+3.19%
Leverage Shares 2X Long CRWV Daily ETF (CRWG)
MINN20.870.20
+0.94%
Mairs & Power Minnesota Municipal Bond ETF (MINN)
ARVR58.360.42
+0.73%
First Trust Indxx Metaverse ETF (ARVR)
FLTW109.15-0.10
-0.09%
Franklin FTSE Taiwan ETF (FLTW)
DWLD44.16-0.48
-1.08%
Davis Select Worldwide ETF (DWLD)

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.68%
VIR - DNLI
52%
Loosely correlated
+0.98%
VCYT - DNLI
50%
Loosely correlated
-4.02%
BCYC - DNLI
50%
Loosely correlated
-3.26%
EDIT - DNLI
49%
Loosely correlated
-1.95%
BEAM - DNLI
48%
Loosely correlated
-0.25%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DMRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DMRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-3.58%
DMRA - NERV
45%
Loosely correlated
-4.93%
ARMP - NERV
43%
Loosely correlated
-9.81%
ANRO - NERV
43%
Loosely correlated
-0.86%
SION - NERV
40%
Loosely correlated
-3.04%
DNLI - NERV
34%
Loosely correlated
-0.68%
More